Hemoadsorption in cardiac surgery, limitations of low-risk patient selection and minimal cytokine levels DOI Creative Commons
Gonzalo Ramírez‐Guerrero, Cristian Pedreros‐Rosales

Critical Care, Год журнала: 2024, Номер 28(1)

Опубликована: Дек. 30, 2024

We read with interest the recent article by Hohn et al., addressing efficacy of hemoadsorption technique in managing cytokine elevation following cardiac surgery, a particular focus on renal outcomes and evolving role extracorporeal blood purification.The REC-CAS study CytoSorb ® SIRAKI02 randomized trial oXiris membranes represent pivotal contributions to this field.Yet, they also share limitations that must be carefully considered [1,2].

Язык: Английский

Systemic inflammation and cardiac surgery: insights from the RECCAS trial DOI Creative Commons
M. P. Luo

Critical Care, Год журнала: 2025, Номер 29(1)

Опубликована: Янв. 2, 2025

Язык: Английский

Процитировано

0
RECCAS, REMOVE, and SIRAKI02: discrepant outcomes and a potential explanation DOI Creative Commons
Patrick M. Honorè,

Sydney Blackman,

Minmin Wang

и другие.

Critical Care, Год журнала: 2025, Номер 29(1)

Опубликована: Янв. 8, 2025

We read with interest the RECCAS trial by Hohn et al., investigating intraoperative hemoadsorption (HA) CytoSorb during cardiopulmonary bypass (CPB) in patients over 65 years undergoing elective on-pump cardiac surgery.In this randomized controlled (RCT), were assigned to either HA or standard care.The primary outcome was difference mean interleukin (IL)-6 serum concentrations upon ICU admission, while secondary outcomes included various clinical and biochemical endpoints.The authors reported no significant differences cytokine levels, organ dysfunction, ICU/hospital lengths of stay, mortality between groups [1].As is less effective CPB without inflammation [2], we turned REMOVE trial, which assessed surgery for infective endocarditis (IE).This RCT used change SOFA score (ΔSOFA) as outcome, comparing total postoperative (up day 9) baseline.REMOVE found reduction dysfunction [2].In contrast, SIRAKI02 evaluated extracorporeal blood purification (BP) oXiris

Язык: Английский

Процитировано

0
The Dark Side of Cardiac and Aortic Interventions: Unveiling Cerebral Microbleeds with Susceptibility-Weighted Imaging DOI Creative Commons
Tommaso Casseri,

Maria Giulia Maccaglia,

Ivano Lombardo

и другие.

Journal of Vascular Diseases, Год журнала: 2025, Номер 4(2), С. 16 - 16

Опубликована: Апрель 7, 2025

Cerebral microbleeds (CMBs) are increasingly detected in patients with aortic and cardiac diseases following transcatheter valve implantation (TAVI), thoracic endovascular repair (TEVAR), or surgery. CMBs can be observed magnetic resonance imaging (MRI) when susceptibility-weighted (SWI) T2*-Gradient-Echo (GRE) sequences used. Differential diagnosis of from other causes, such as cerebral amyloid angiopathy (CAA), is crucial because its clinical implications, particularly for anticoagulation management. A literature search was conducted using publicly available online databases to identify relevant studies this review. The selection criteria focused on publications utilizing MRI T2*-GRE SWI detect procedures. extracted data included study characteristics, lesion distribution, associated factors. Ten were review, 50% analyzing a prospective cohort. hypointensities after vascular procedures often showed lobar thus complicating the differential “probable” CAA. However, seem predominantly located subcortical white matter (SWM), unlike CAA, commonly not alterations. Furthermore, correlate prolonged procedural duration, especially case cardiopulmonary bypass, therapy. Regarding etiology, various hypotheses have been proposed, most widely accepted being microhemorrhagic. common finding procedures, either surgical endovascular. Their distribution patterns may aid differentiating CAA-related lesions, important implications strategies. Identifying characterizing these lesions essential optimizing postoperative

Язык: Английский

Процитировано

0
Hemoadsorption in cardiac surgery, limitations of low-risk patient selection and minimal cytokine levels DOI Creative Commons
Gonzalo Ramírez‐Guerrero, Cristian Pedreros‐Rosales

Critical Care, Год журнала: 2024, Номер 28(1)

Опубликована: Дек. 30, 2024

We read with interest the recent article by Hohn et al., addressing efficacy of hemoadsorption technique in managing cytokine elevation following cardiac surgery, a particular focus on renal outcomes and evolving role extracorporeal blood purification.The REC-CAS study CytoSorb ® SIRAKI02 randomized trial oXiris membranes represent pivotal contributions to this field.Yet, they also share limitations that must be carefully considered [1,2].

Язык: Английский

Процитировано

0